Chapter 40—Comprehensive Emergency Medical Services Systems Regulations

19 CSR 30-40

B. Thrombolytic administration time which is the time from first medical contact or pre-hospital electrocardiogram STEMI identification to hospital door time and the time from hospital door to needle time; (I-R, II-R, III-R, IV-R)

C. Number of STEMI patients presenting within the treatment window for percutaneous coronary interventions and/or thrombolytic administration; (I-R, II-R, III-R, IV-R)

D. Number of eligible STEMI patients treated with percutaneous coronary intervention and/or thrombolytic administration; and (I-R, II-R, III-R, IV-R)

E. Time from when STEMI patient presents at the receiving STEMI center to time STEMI patient is in the operating room at the receiving STEMI center. (I-R, II-R if cardiac surgical capability)

2. The STEMI center shall at least quarterly conduct a regular morbidity and mortality review. (I-R, II-R, III-R, IV-R)

3. The STEMI center shall conduct a review of the reports generated by the department from the Missouri STEMI registry. (I-R, II-R, III-R, IV-R)

4. The STEMI center shall conduct a monthly review of its pre-hospital STEMI care including inter-facility transfers. (I-R, II-R, III-R, IV-R)

5. The STEMI center shall participate in the emergency medical services regional system of STEMI care. (I-R, II-R, III-R, IV-R)

6. The STEMI center shall review cases of STEMI patients remaining greater than thirty (30) minutes at the referring hospital prior to transfer as a part of its performance improvement and patient safety program. (I-R, II-R, III-R, IV-R)

7. The STEMI center shall review and monitor the core competencies of its physicians, practitioners, and nurses. (I-R, II-R, III-R, IV-R)

(B) It is recommended that level I and II STEMI centers establish a cardiology outreach program that provides physicians in the outlying areas with telephone access to the cardiology program. (I-R, II-R)

(C) STEMI centers shall establish a patient and public education program to promote STEMI prevention and awareness of signs and symptoms. (I-R, II-R, III-R, IV-R)

(D) Level I, II, and III STEMI centers shall establish a professional education outreach program in catchment areas to provide training and other supports to improve care of STEMI patients. (I-R, II-R, III-R)

(E) Each STEMI center shall establish a training program on caring for STEMI patients for professionals in the STEMI center that includes at least the following:

1. A procedure for training nurses and clinical staff to be credentialed in STEMI care; (I-R, II-R, III-R, IV-R)

2. A mechanism to assure that all nurses providing care to STEMI patients complete a minimum of required continuing education to become credentialed in STEMI care; and (I-R, II-R, III-R, IV-R)

3. The content and format of any STEMI continuing education courses developed and offered by the STEMI center shall be developed with the oversight of the STEMI center medical director. (I-R, II-R, III-R, IV-R)

(F) STEMI centers shall provide and monitor timely feedback to the emergency medical services providers and referring hospital(s), if involved. This feedback shall include, at least, diagnosis, treatment, and referring hospital, if involved. It is recommended that the feedback be provided within seventy-two (72) hours of admission to the hospital. When emergency medical services does not provide patient care data on patient arrival or in a timely fashion (recommended within three (3) hours of patient delivery), this time frame shall not apply. (I-R, II-R, III-R, IV-R)

(G) The STEMI centers shall be actively involved in local and regional emergency medical services systems by providing training and clinical educational resources. (I-R, II-R, III-R, IV-R)

6. Standards for the Programs in STEMI Research for STEMI Center Designation.

(A) The STEMI center and its staff shall support an ongoing research program in STEMI as evidenced by any of the following:

1. Production of evidence based reviews of the STEMI program’s process and clinical outcomes; (I-R)

2. Publications in peer-reviewed journals; (I-R)

3. Reports of findings presented at regional or national meetings; (I-R)

4. Receipt of grants for study of STEMI care; (I-R)

5. Participation in multi-center studies; or (I-R)

6. Epidemiological studies and individual case studies. (I-R)

(B) The STEMI center shall agree to cooperate and participate with the department for the purpose of developing prevention programs. (I-R, II-R, III-R, IV-R)


19 CSR 30-40.770 Community-based or Regional Plan for Emergency Medical Services for Trauma, ST-Segment Elevation Myocardial Infarction (STEMI), or Stroke

PURPOSE: This rule establishes the procedures for the submission of a community-based or regional plan for the transportation of patients to stroke, STEMI, or trauma centers.

(1) A community or region developing its own transportation plan for stroke, STEMI, and trauma patients may submit a plan at any time and shall ensure that it complies with section 190.200.3, RSMo. Such a plan shall also—

(A) Identify the geographic boundaries of the area covered by the plan;

(B) Designate, and provide contact information for, an individual, plan’s designee who will serve as the plan’s point of contact throughout the plan’s approval and administration process; and

(C) Identify individuals involved in the drafting, planning, and/or consultation of the plan, who shall collectively be known as the “planning committee.”

(2) Upon completion of a community-based or regional plan, the plan shall be submitted to the chair of the regional emergency medical services advisory committee defined by section 190.102, RSMo, and the regional emergency medical services medical director defined by section 190.103, RSMo, for the geographic area covered by the plan. Upon receipt of a plan submitted pursuant to the provisions of section 190.200, RSMo, the chair and medical director shall forward the plan to the emergency medical services medical director’s advisory committee (the committee) as defined by section 190.103, RSMo, for consideration. Within forty-five (45) days of receipt of a community-based or regional plan, the committee shall meet and complete its review of the plan. Upon a finding of good cause, the chair of the committee may grant the committee a reasonable extension of time for review of the plan.

(3) In reviewing a community-based or regional plan, the committee shall determine whether the plan meets the requirements of section 190.200.3, RSMo, and this rule.

(4) At the conclusion of its review, the committee shall vote on the question of whether
to recommend or not recommend the plan for approval. If a majority of the committee votes to recommend the plan for approval, said recommendation shall constitute *prima facie* evidence that the plan meets the requirements of section 190.200.3, RSMo, and should be approved. The committee shall attach such conditions (such as regular analysis and reporting of medical outcomes to the committee) to its recommendation for approval as it deems appropriate to ensure that the plan continues to meet the requirements of Chapter 190, RSMo. If a majority of the committee votes to not recommend the plan, that decision, with an explanation of the reason(s) for the decision, shall be provided in writing to the plan’s designee. A community or region receiving a non-recommendation by the committee may modify its plan according to the committee’s reason(s) for non-recommendation and resubmit the plan within thirty (30) days directly to the committee.

(5) Following recommendation of a community-based or regional plan, the committee shall forward the plan to the Director of the Department of Health and Senior Services (director) for approval. The director shall have thirty (30) days to review the plan for its compliance with section 190.200.3, RSMo. At the conclusion of the review, the director shall approve or disapprove the plan. If the director disapproves the plan, the reason(s) for disapproval shall be provided in writing to the plan’s designee along with the right to appeal the director’s decision. The director’s decision shall be the final agency action. A community or region whose plan is not approved by the director may modify its plan according to the director’s reason(s) for disapproval and resubmit the plan within thirty (30) days directly to the committee and follow the approval process as outlined herein.

(6) Once a plan is approved by the director, the planning committee shall—

(A) Notify all agencies impacted by the plan of the manner in which emergency medical care is modified within the region based on the plan;

(B) Monitor per the plan the related medical and system outcomes and regional resources and capacity;

(C) Revise the plan when indicated based on medical and system outcomes, emerging clinical research or guidelines, or when revision is indicated based on changes in capacity or other related issues and submit through the approval process as outlined herein; and

(D) Notify the committee and department at least thirty (30) days before ceasing to use the plan.

**19 CSR 30-40.780 Definitions and Abbreviations Relating to the Transport Protocol for Stroke and the Transport Protocol for ST-Segment Elevation Myocardial Infarction (STEMI) Patients**

**PURPOSE:** This rule defines terminology related to the state transport protocol for stroke and the state transport protocol for STEMI.

(1) The following definitions and abbreviations shall be used in the interpretation of the rule in 19 CSR 30-40.790:

(A) Field is the specific area or location, outside of the hospital, where an injury, accident, or medical emergency occurs requiring immediate assistance of medical personnel for the purpose of treating or transporting the sick or injured to another location for treatment;

(B) Local and regional process is the process that has been established and agreed upon specifically pertaining to a local city, town, or small district, or a combination of localities forming a regional area. This is not the community-based or regional plan;

(C) Lytics are thrombolytic drugs, including recombinant tissue plasminogen activator, used to dissolve clots blocking flow in a blood vessel. These lytic/thrombolytic drugs are used in the treatment of acute ischemic stroke and acute myocardial infarction;

(D) Lytic/therapeutic window is the period of time during which lytics can be administered following the onset of symptoms in order to reduce brain or heart injury;

(E) Lytic therapy (fibrinolysis/thrombolysis) is drug therapy used to dissolve clots blocking flow in a blood vessel. It refers to drugs used for that purpose, including recombinant tissue plasminogen activator. This type of therapy can be used in the treatment of acute ischemic stroke and acute myocardial infarction;

(F) Lytic/thrombolytic ineligible patients are those patients identified as ineligible for lytic/thrombolytic therapy due to specific contraindications. An appropriate course of treatment will be utilized when lytic/thrombolytic therapy is contraindicated;

(G) Out of the lytic/therapeutic or potential therapeutic window is the period of time following the accepted time (lytic/therapeutic window and potential therapeutic window) frames for specific therapies for a patient suffering an ischemic stroke;

(H) Outside of the percutaneous coronary intervention (PCI) window is the period of time following the accepted time frame in which PCI is most advantageous and recommended;

(I) Percutaneous coronary intervention (PCI) is a procedure used to open or widen narrowed or blocked blood vessels to restore blood flow supplying the heart;

(J) Percutaneous coronary intervention (PCI) window is a time frame in which PCI is most advantageous and recommended;

(K) Potential therapeutic window is the period of time after the accepted window for lytic therapy has expired in which interventional therapy may be beneficial in restoring blood flow during an ischemic stroke; and

(L) Recombinant tissue plasminogen activator (t-PA also known as rt-PA) is a thrombolytic (clot-dissolving) agent, the goal of which is to destroy the thrombus (clot) within the blood vessel by stimulating fibrinolysis (clot breakdown) to allow restoration of blood flow.
